These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Long-term effect of intravitreal aflibercept treatment on choroidal vascularity index in neovascular age-related macular degeneration. Alis A; Guler Alis M Photodiagnosis Photodyn Ther; 2021 Dec; 36():102582. PubMed ID: 34648995 [TBL] [Abstract][Full Text] [Related]
3. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration. Yun C; Oh J; Ahn J; Hwang SY; Lee B; Kim SW; Huh K Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1693-702. PubMed ID: 26781585 [TBL] [Abstract][Full Text] [Related]
4. Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: Ranibizumab versus aflibercept. Kaya F J Fr Ophtalmol; 2017 Dec; 40(10):832-838. PubMed ID: 29113742 [TBL] [Abstract][Full Text] [Related]
5. Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes. Gharbiya M; Giustolisi R; Marchiori J; Bruscolini A; Mallone F; Fameli V; Nebbioso M; Abdolrahimzadeh S Curr Eye Res; 2018 Mar; 43(3):391-396. PubMed ID: 29166140 [TBL] [Abstract][Full Text] [Related]
6. Choroidal Thickness Changes After Intravitreal Antivascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration: Ranibizumab Versus Aflibercept. Gharbiya M; Cruciani F; Mariotti C; Grandinetti F; Marenco M; Cacace V J Ocul Pharmacol Ther; 2015; 31(6):357-62. PubMed ID: 26133059 [TBL] [Abstract][Full Text] [Related]
7. Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration. Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Kawasaki R; Sekiryu T; Okada AA; Iida T Am J Ophthalmol; 2015 Apr; 159(4):627-33. PubMed ID: 25555799 [TBL] [Abstract][Full Text] [Related]
8. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results. Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967 [TBL] [Abstract][Full Text] [Related]
9. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice. Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633 [TBL] [Abstract][Full Text] [Related]
10. The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography. Abri Aghdam K; Seidensticker F; Pielen A; Framme C; Junker B Lasers Surg Med; 2016 Sep; 48(7):668-77. PubMed ID: 27111455 [TBL] [Abstract][Full Text] [Related]
11. Using optical coherence tomography angiography in assessment of the anti-vascular endothelial growth factor effect for pathological vascular tissue in age-related macular degeneration and polypoidal choroidal vasculopathy. Shen YS; Cheng CK Eur J Ophthalmol; 2021 May; 31(3):1267-1280. PubMed ID: 32228025 [TBL] [Abstract][Full Text] [Related]
13. Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study. Kim JH; Lee TG; Chang YS; Kim CG; Cho SW Br J Ophthalmol; 2016 Dec; 100(12):1634-1639. PubMed ID: 26951770 [TBL] [Abstract][Full Text] [Related]
14. Aflibercept therapy in eyes with neovascular age-related macular degeneration and its effect on choroidal thickness. Sariyeva Ismayılov A; Esen E; Sızmaz S; Demircan AN Clin Exp Optom; 2019 Nov; 102(6):617-620. PubMed ID: 30793798 [TBL] [Abstract][Full Text] [Related]
15. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study). Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357 [TBL] [Abstract][Full Text] [Related]
16. Anatomical effects of intravitreal anti-vascular endothelial growth factor injections on inner layers of the lesion-free retina. Demir N; Sevincli S; Kayhan B; Sonmez M Cutan Ocul Toxicol; 2021 Jun; 40(2):135-139. PubMed ID: 33944638 [TBL] [Abstract][Full Text] [Related]
18. Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection. Saito M; Kano M; Itagaki K; Ise S; Imaizumi K; Sekiryu T Jpn J Ophthalmol; 2016 Jan; 60(1):35-41. PubMed ID: 26350229 [TBL] [Abstract][Full Text] [Related]
19. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration. Brynskov T; Munch IC; Larsen TM; Erngaard L; Sørensen TL Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617 [TBL] [Abstract][Full Text] [Related]
20. Improvements of Retinal Sensitivity after Intravitreal Injection of Aflibercept in Eyes with Neovascular Age-Related Macular Degeneration with or without Polypoidal Choroidal Vasculopathy. Nizawa T; Kitahashi M; Baba T; Iwase T; Kubota-Taniai M; Hattori Y; Shiko Y; Kawasaki Y; Iwase T; Sato T; Ogawa S; Sugawara T; Yamamoto S Ophthalmologica; 2021; 244(4):347-360. PubMed ID: 34015785 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]